Cutera (CUTR) 10-Q 10 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001162461
Entity Registrant Name	CUTERA INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	000-50644
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0492262
Entity Address, Address Line One	3240 Bayshore Blvd.
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	415
Local Phone Number	657-5500
Title of 12(b) Security	Common Stock ($0.001 par value)
Trading Symbol	CUTR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,803,274

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 164,932	$ 47,047
Accounts receivable, net of allowance for credit losses of $1,611 and $1,598, respectively	24,151	21,962
Inventories	34,578	28,508
Other current assets and prepaid expenses	10,339	8,779
Total current assets	234,000	106,296
Property and equipment, net	2,373	2,299
Deferred tax asset	598	643
Operating lease-right-of-use assets	16,570	17,076
Goodwill	1,339	1,339
Other long-term assets	4,853	5,080
Total assets	259,733	132,733
Current liabilities:
Accounts payable	5,031	6,684
Accrued liabilities	41,329	31,079
Operating lease liabilities	2,351	2,260
PPP loan payable	6,352	3,630
Extended warranty liability	1,039	1,216
Deferred revenue	10,019	9,489
Total current liabilities	66,121	54,358
Deferred revenue, net of current portion	1,718	1,748
Operating lease liabilities, net of current portion	15,394	15,950
PPP loan payable, net of current portion	851	3,555
Convertible notes, net of unamortized debt issuance costs of $4,665	133,585	0
Other long-term liabilities	434	242
Total liabilities	218,103	75,853
Commitments and Contingencies (Notes 12)
Stockholders’ equity:
Common stock, $0.001 par value; authorized: 50,000,000 shares; issued and outstanding: 17,801,926 and 17,679,232 shares at March 31, 2021 and December 31, 2020, respectively	18	18
Additional paid-in capital	102,206	117,097
Accumulated deficit	(60,594)	(60,235)
Total stockholders’ equity	41,630	56,880
Total liabilities and stockholders’ equity	$ 259,733	$ 132,733

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Trade accounts receivable, allowance	$ 1,611	$ 1,598
Unamortized debt issuance costs	$ 4,665
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	17,801,926	17,679,232
Common stock, outstanding (in shares)	17,801,926	17,679,232

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net revenue:
Revenue	$ 49,668,000	$ 32,239,000
Cost of revenue:
Cost of revenue	21,958,000	17,903,000
Gross profit	27,710,000	14,336,000
Operating expenses:
Sales and marketing	15,068,000	14,789,000
Research and development	4,112,000	3,870,000
General and administrative	7,365,000	7,806,000
Total operating expenses	26,545,000	26,465,000
Income (loss) from operations	1,165,000	(12,129,000)
Amortization of debt issuance costs	(52,000)	0
Interest on Convertible notes	(191,000)	0
Other expense, net	(1,023,000)	(207,000)
Total interest and other expense, net	(1,266,000)	(207,000)
Loss before income taxes	(101,000)	(12,336,000)
Income tax expense	258,000	78,000
Net loss	$ (359,000)	$ (12,414,000)
Net loss per share:
Net loss per share, basic and diluted (in dollars per share)	$ (0.02)	$ (0.86)
Weighted-average number of shares used in per share calculations:
Basic and Diluted (in shares)	17,768	14,433
Product [Member]
Net revenue:
Revenue	$ 43,551,000	$ 26,391,000
Cost of revenue:
Cost of revenue	18,331,000	14,103,000
Service [Member]
Net revenue:
Revenue	6,117,000	5,848,000
Cost of revenue:
Cost of revenue	$ 3,627,000	$ 3,800,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss	$ (359)	$ (12,414)
Available-for-sale investments
Reclassification adjustment for losses on investments recognized during the period	0	61
Net change in unrealized loss on available-for-sale investments	0	61
Other comprehensive gain, net of tax	0	61
Comprehensive loss	$ (359)	$ (12,353)

Consolidated Statements of Chan

Consolidated Statements of Changes In Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2019	14,315,586
Balance at Dec. 31, 2019	$ 14	$ 82,346	$ (36,358)	$ (60)	$ 45,942
Exercise of stock options (in shares)	22,291
Exercise of stock options		200	0	0	200
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes (in shares)	240,269
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	$ 1	(2,234)	0	0	(2,233)
Stock-based compensation expense	0	1,980	0	0	1,980
Net loss	0	0	(12,414)	0	(12,414)
Net change in unrealized loss on available-for-sale investments	$ 0	0	0	61	61
Balance (in shares) at Mar. 31, 2020	14,578,146
Balance at Mar. 31, 2020	$ 15	82,292	(48,772)	1	$ 33,536
Balance (in shares) at Dec. 31, 2020	17,679,232				17,679,232
Balance at Dec. 31, 2020	$ 18	117,097	(60,235)	0	$ 56,880
Exercise of stock options (in shares)	24,090				24,090
Exercise of stock options	$ 0	396	0	0	$ 396
Purchase of capped call	$ 0	(16,134)	0	0	(16,134)
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes (in shares)	98,604
Issuance of common stock in settlement of restricted and performance stock units, net of shares withheld for employee taxes	$ 0	(999)	0	0	(999)
Stock-based compensation expense	0	1,846	0	0	1,846
Net loss	$ 0	0	(359)	0	(359)
Net change in unrealized loss on available-for-sale investments					$ 0
Balance (in shares) at Mar. 31, 2021	17,801,926				17,801,926
Balance at Mar. 31, 2021	$ 18	$ 102,206	$ (60,594)	$ 0	$ 41,630

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (359)	$ (12,414)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	1,846	1,980
Depreciation and amortization	361	360
Amortization of contract acquisition costs	545	717
Amortization of debt issuance costs	52	0
Impairment of capitalized cloud computing costs	182	0
Change in deferred tax asset	45	15
Provision for credit losses	218	590
Gain on sale of property and equipment	(59)	0
Change in right-of-use asset	604	645
Other	0	35
Changes in assets and liabilities:
Accounts receivable	(2,407)	5,306
Inventories	(6,021)	(3,020)
Other current assets and prepaid expenses	(1,560)	807
Other long-term assets	(500)	(207)
Accounts payable	(1,653)	1,919
Accrued liabilities	10,199	(6,567)
Extended warranty liabilities	(177)	(234)
Operating lease liabilities	(563)	(645)
Deferred revenue	500	(1,253)
Net cash provided by (used in) operating activities	1,253	(11,966)
Cash flows from investing activities:
Acquisition of property, equipment, and software	(101)	(230)
Proceeds from disposal of property and equipment	52	0
Proceeds from maturities of marketable investments	0	6,800
Purchase of marketable investments	0	(3,930)
Net cash provided by (used in) investing activities	(49)	2,640
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan	396	201
Purchase of capped call	(16,134)	0
Proceeds from issuance of Convertible notes	138,250	0
Payment of issuance costs of Convertible notes	(4,717)	0
Taxes paid related to net share settlement of equity awards	(999)	(2,234)
Payments on finance lease obligations	(115)	(183)
Net cash provided by (used in) financing activities	116,681	(2,216)
Net increase (decrease) in cash and cash equivalents	117,885	(11,542)
Cash and cash equivalents at beginning of period	47,047	26,316
Cash and cash equivalents at end of period	164,932	14,774
Supplemental disclosure of non-cash items:
Assets acquired under finance lease	25	0
Assets acquired under operating lease	123	0
Debt issuance costs accrued	452	0
Income tax paid	$ 458	$ 75

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1. Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: enlighten, excel, Secret PRO, Juliet, Secret RF, truSculpt xeo Titan, truSculpt 3D,truSculpt truSculpt flex Secret PRO, Juliet Secret RF third Titan, truSculpt 3D, truSculpt flex The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company also maintains regional distribution centers (“RDCs”) in selection locations across the U.S. These RDCs serve as forward warehousing for systems and service parts in various geographies. The Company markets sells and services the Company’s products through direct sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland, and the United Kingdom. Sales and services outside of these direct markets are made through a worldwide distributor network in over 42 Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not In March 2020 , 19 19 2020 December 31, 2020. third 2020, 19 2021, 19 19 19 no three March 31, 2021 . COVID–19 The Company has experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales might have been the result of changes in customers’ spending habits to purchase more aesthetic treatments which could be applied at home due to limitations on in-person aesthetic procedures, social distancing and mask wearing requirements due to the COVID- 19 may 19 may Unaudited Interim Financial Information In the opinion of the Company, the accompanying unaudited Condensed consolidated financial statements included in this report reflect all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of its Condensed consolidated statements of financial position as of March 31, 2021 2020, three March 31, 2021, 2020. December 31, 2020 not not 10 December 31, 2020 March 23, 2021. Accounting Policies These unaudited Condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not 10 December 31, 2020 March 23, 2021. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the notes to Condensed consolidated financial statements refer to the Company’s continuing operations. Note 13 The Company issued $138.3 million of convertible senior notes ("Notes" or "Convertible notes") in a private placement offering on March 5, 2021. 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 no The costs associated with issuance of the Convertible notes, including underwriters’ fees are presented in the Condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. The debt issuance costs are amortized over the life of the Convertible notes as additional non-cash interest expense. In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally designated to reduce the potential dilution of the Company's common stock upon any conversion of the Notes. The capped calls were purchased for $16.1 million and recorded as a reduction to additional paid in capital in the Condensed consolidated balance sheet as of March 31, 2021. Use of Estimates The preparation of Condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, assumptions regarding variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Recently Adopted Accounting Pronouncements In December 2019, No. 2019 12 Income Taxes (Topic 740 three March 31, 2021. not In August 2020, No. 2020 06, 470 815 no not not may January 1, 2021. 13

Note 2 - Cash, Cash Equivalents

Note 2 - Cash, Cash Equivalents	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Cash, Cash Equivalents, and Marketable Securities [Text Block]	Note 2. The following table summarizes the Company's cash and cash equivalents (in thousands): (Dollars in thousands) March 31, 2021 December 31, 2020 Cash and cash equivalents $ 164,932 $ 47,047 The Company has no marketable securities as of March 31, 2021 December 31, 2020.

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3. Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three may 820, ● Level 1: ● Level 2: 1 not not third ● Level 3: no 3 In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. See Note 13 2026.

Note 4 - Balance Sheet Details

Note 4 - Balance Sheet Details	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 4. Inventories As of March 31, 2021 December 31, 2020, March 31, 2021 December 31, 2020 Raw materials $ 15,335 $ 14,874 Work in process 1,359 1,030 Finished goods 17,884 12,604 Total $ 34,578 $ 28,508 Accrued Liabilities As of March 31, 2021 December 31, 2020, March 31, 2021 December 31, 2020 Accrued payroll and related expenses $ 12,558 $ 12,197 Sales and marketing accruals 3,134 2,352 Accrued inventory in transit 7,501 2,476 Product warranty 3,351 2,908 Accrued sales tax 6,935 5,343 Other accrued liabilities 7,850 5,803 Total $ 41,329 $ 31,079 Product Remediation Liability During the fourth 2018, one one 2018. As of March 31, 2021 December 31 2020, three March 31, 2021 $0 three March 31, 2020 Nil

Note 5 - Warranty and Extended

Note 5 - Warranty and Extended Service Contract	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	Note 5. The Company has a direct field service organization in North America (including Canada). Internationally, the Company provides direct service support in Australia, Belgium, France, Germany, Hong Kong, Japan, and Switzerland, as well as through third not third After the original warranty period, maintenance and support are offered on an extended service contract basis or on a time and materials basis. The Company provides for the estimated cost to repair or replace products under standard warranty at the time of sale. Costs incurred in connection with extended service contracts are recognized at the time when costs are incurred, except the one December 31, 2018 one The following table provides the changes in the product warranty accrual for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 (1) Beginning Balance $ 2,908 $ 4,401 Add: Accruals for warranties issued during the period 1,525 860 Less: Settlements made during the period (1,082 ) (1,863 ) Ending Balance $ 3,351 $ 3,398 ( 1 The ending product warranty accrual balance excludes $1.0 million and $1.8 million as of March 31, 2021 2020, one one s legacy products. The $1.1 million and $1.9 million of settlements made in the three March 31, 2021 2020, one

Note 6 - Deferred Revenue

Note 6 - Deferred Revenue	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Contract with Customer Liability [Text Block]	Note 6. The Company records deferred revenue when revenue is to be recognized subsequent to invoicing. For extended service contracts, the Company generally invoices customers at the beginning of the extended service contract term. The Company’s extended service contracts typically have one two three March 31, 2021 12 The following table provides changes in the deferred revenue balance for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Balance at beginning of quarter $ 11,237 $ 14,222 Add: Payments received 4,929 3,571 Less: Revenue (445 ) (592 ) Less: Revenue included in the beginning balance and recognized as revenue in the current quarter (3,984 ) (4,232 ) Balance at end of quarter $ 11,737 $ 12,969 Costs for extended service contracts were $2.0 million and $2.2 million for the three March 31, 2021 2020,

Note 7 - Revenue

Note 7 - Revenue	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 7. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time. Revenue from performance obligations that are transferred to customers over time accounted for approximately 12% and 18% respectively, of the Company’s total revenue for the three March 31, 2021 2020. The Company has certain system sale arrangements that contain multiple products and services. For these bundled sale arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct. The Company’s products and services are distinct if a customer can benefit from the product or service on its own or with other resources that are readily available to the customer, and if the Company’s promise to transfer the products or service to the customer is separately identifiable from other promises in the sale arrangements. The Company’s system sale arrangements can include all or a combination of the following performance obligations: the system and software license (considered as one For the Company’s system sale arrangements that include an extended service contract, the period of service commences at the expiration of the Company’s standard warranty offered at the time of the system sale. The Company considers the extended service contracts terms in the arrangements that are legally enforceable to be performance obligations. Other than extended service contracts and marketing services, which are satisfied over time, the Company generally satisfies all performance obligations at a point in time. Systems, system accessories (hand pieces), service contracts, training, and time and materials services are also sold on a stand-alone basis, and these performance obligations are satisfied at a point in time. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price basis. Nature of Products and Services Systems Systems revenue is generated from the sale of systems and from the sale of upgrades to existing systems. A system consists of a console that incorporates a universal graphic user interface, a laser or other energy-based module, control system software and high voltage electronics, as well as one Pearl Pearl Fractional The Company offers customers the ability to select the system that best fits their practice at the time of purchase and then to cost-effectively add applications to their system as their practice grows. This provides customers the flexibility to upgrade their systems whenever they choose and provides the Company with a source of additional Systems revenue. The system or upgrade and the right to use the embedded software represent a single performance obligation as the software license is integral to the functionality of the system or upgrade. For systems sold directly to end-customers that are credit approved, revenue is recognized when the Company transfers control to the end-customer, which occurs when the product is shipped to the customer or when the customer receives the product, depending on the nature of the arrangement. When collectability is not The Company typically receives payment for its system consoles and other accessories within 30 Skincare products The Company sells third third 90 Consumables and other accessories The Company classifies its customers' purchases of replacement cycles for truSculpt iD truSculpt flex, truSculpt 3D Secret PRO, Juliet, Secret RF, Juliet Secret RF Equipment leasing The Company leases equipment to customers through membership programs and receives a fixed monthly fee over the term of the arrangement. The Company classifies its lease income as product revenue. The Company recognizes lease income over the term of the lease if the lease is classified as an operating lease. For agreements that grant customers the right to purchase the leased system, the Company typically classifies the lease as a sales-type lease as the Company has determined it is reasonably certain that the customer will exercise the purchase option. On the commencement of sales-type leases, the Company recognizes revenue upfront in product revenue and the corresponding receivables recorded in other current assets and prepaid expenses on the Condensed consolidated balance sheets (See Note 11 no three March 31, 2021. not three March 31, 2021. Extended contract services The Company offers post-warranty services to its customers through extended service contracts that cover parts and labor for a term of one, two, or three Training Sales of systems to customers include training on the use of the system to be provided within 180 not The Company classifies as product revenue the sales of systems, system upgrades, hand pieces, hand piece refills (applicable to Titan truSculpt third Customer Marketing Support In North America, the Company offers marketing and consulting phone support to its customers across all system platforms. These customer marketing support services include a practice development model and marketing training, performed remotely with ongoing phone consultations for six six Significant Judgments The determination of whether two one may While the Company’s purchase agreements do not The Company determines standalone selling price ("SSP") for each performance obligation as follows: ● Systems: The SSPs for systems are based on directly observable sales in similar circumstances to similar customers. ● Extended warranty/Service contracts: SSP is based on observable price when sold on a standalone basis (by customer type). Loyalty Program The Company has a customer loyalty program for qualified customers located in the U.S. and Canada. Under the loyalty program, customers accumulate points based on their purchasing levels which can be redeemed for such rewards as the right to attend the Company’s advanced training event for truSculpt March 31, 2021 December 31, 2020 , Deferred Sales Commissions Incremental costs of obtaining a contract, which consist primarily of commissions and related payroll taxes, are capitalized and amortized on a straight-line basis over the expected period of benefit, except for costs that are recognized when product is sold. The Company uses the portfolio method to recognize the amortization expense related to these capitalized costs related to initial contracts and such expense is recognized over a period associated with the revenue of the related portfolio, which is generally two three Total capitalized costs as of March 31, 2021 December 31, 2020 three March 31, 2021 2020

Note 8 - Stockholders' Equity a

Note 8 - Stockholders' Equity and Stock-based Compensation Expense	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 8. Equity and Stock-based Compensation Expense The Company’s equity incentive plans are broad-based, long-term programs intended to attract and retain talented employees and align stockholder and employee interests. In June 2019, 2004 2019 “2019 June 2020, 2019 The Company’s Board of Directors granted its executive officers and senior management 88,588 performance stock units (“PSUs”) during the three March 31, 2021. three March 31, 2021 2021 The Company’s Board of Directors also granted its executive officers and senior management 56,597 RSUs and 68,673 non-qualified stock options (“NQs”) during the three March 31, 2021. four one fourth first January 1, 2021 1/36 During the quarter ended September 30, 2019 2019 2022 2019 2020 2021 2020 2019 2022. March 31, 2021, 2019, 2020 2021 2019 three March 31, 2020. None 2020 2022 not March 31, 2020 2022. April 28, 2021, 2020 second June 30, 2021. On August 2, 2020 , April 28, 2021. Under the 2019 three March 31, 2021, As of March 31, 2021 , may Activity under the 2019 Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Price Balance, December 31, 2020 1,085,170 217,007 $ 22.35 Stock awards granted (234,227 ) 68,673 32.87 Options exercised - (24,090 ) 16.41 Options canceled 2,500 (2,500 ) 39.30 Stock awards canceled 58,232 - - Balance, March 31, 2021 911,675 259,090 $ 25.53 Stock-based Compensation Expense Stock-based compensation expense by department recognized during the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Cost of revenue $ 144 $ 290 Sales and marketing 721 719 Research and development 301 321 General and administrative 680 650 Total stock-based compensation expense $ 1,846 $ 1,980

Note 9 - Net Loss Per Share

Note 9 - Net Loss Per Share	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9. Basic earnings per share (“EPS”) is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method or the if-converted method. Dilutive potential common shares include outstanding stock options, stock awards, shared performance stock awards, and conversion shares under the Convertible notes. As of March 31, 2021, three March 31, 2021 2020, The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Numerator: Net loss $ (359 ) $ (12,414 ) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 17,768 14,433 Dilutive effect of incremental shares and share equivalents - - Weighted average shares of common stock outstanding used in computing net loss per share, diluted 17,768 14,433 Net loss per share: Net loss per share, basic and diluted $ (0.02 ) $ (0.86 ) The following numbers of shares outstanding, prior to the application of the treasury stock method, were excluded from the computation of diluted net loss per common share for the periods presented because including them would have had an anti-dilutive effect (in thousands): Three Months Ended March 31, 2021 2020 Convertible notes(1)(2) 4,167 - Options to purchase common stock 245 276 Restricted stock units 585 669 Performance stock units 92 216 Employee stock purchase plan shares 30 71 Total 5,119 1,232 ( 1 Anti-dilutive convertible notes were calculated under the if-converted method for the three March 31, 2021. ( 2 The Company entered into capped call transactions with certain financial institutions, which are generally designated to reduce common stock dilution upon conversion of the Convertible notes. The capped call transactions are excluded from the computation of diluted net loss per common share as their effect would be anti-dilutive.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10. For the three March 31, 2021, three March 31, 2020. The Company's income tax expense for the three March 31, 2021

Note 11 - Leases

Note 11 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Leases [Text Block]	Note 11. The Company is a party to certain operating and finance leases for vehicles, office space and storages facilities. The Company’s operating leases consist of office space, as well as storage facilities and finance leases consist of automobiles. The Company’s leases generally have remaining terms of 1 to 10 years, some of which include options to renew the leases for up to 5 years. The Company leases space for operations in the United States, Japan, Belgium, France and Spain. In addition to the above facility leases, the Company also routinely leases automobiles for certain sales and field service employees under finance leases. The Company determines if a contract contains a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not not The Company recognizes expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce the Company’s right-of-use (“ROU”) asset related to the lease. These are amortized through the ROU asset as reductions of expense over the lease term. Supplemental balance sheet information related to leases was as follows (in thousands): Leases Classification March 31, 2021 December 31, 2020 Assets Right-of-use assets Operating lease assets $ 16,570 $ 17,076 Finance lease Property and equipment, net (1) 418 467 Total leased assets $ 16,988 $ 17,543 ( 1 Liabilities March 31, 2021 December 31, 2020 Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,351 $ 2,260 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 15,394 15,950 Total Operating lease liabilities $ 17,745 $ 18,210 Finance lease liabilities Finance lease liabilities, current Accrued liabilities (1) $ 418 $ 370 Finance lease liabilities, non-current Other long-term liabilities 434 241 Total Finance lease liabilities $ 852 $ 611 ( 1 Finance lease liabilities included in accrued liabilities in the Condensed consolidated balance sheets. Lease costs during the three March 31, 2021 2020 ( Three Months Ended March 31, Lease costs 2021 2020 Finance lease cost Amortization expense $ 127 $ 149 Finance lease cost Interest for finance lease $ 14 $ 19 Operating lease cost Operating lease expense $ 878 $ 728 Cash paid for amounts included in the measurement of lease liabilities during the three March 31, 2021 2020 Three Months Ended March 31, Cash paid for amounts included in the measurement of lease liabilities 2021 2020 Operating cash flow Finance lease $ 14 $ 19 Financing cash flow Finance lease $ 115 $ 120 Operating cash flow Operating lease $ 772 $ 727 Facility leases Maturities of facility leases were as follows as of March 31, 2021 ( As of March 31, 2021 Amount Remainder of 2021 $ 2,327 2022 3,152 2023 3,189 2024 2,879 2025 2,875 2026 and thereafter 6,308 Total lease payments 20,730 Less: imputed interest 2,985 Present value of lease liabilities $ 17,745 Vehicle Leases As of March 31, 2021, As of March 31, 2021 Amount Remainder of 2021 $ 342 2022 377 2023 141 Total lease payments 860 Less: imputed interest 8 Present value of lease liabilities $ 852 Weighted-average remaining lease term and discount rate, as of March 31, 2021, Lease Term and Discount Rate March 31, 2021 Weighted-average remaining lease term (years) Operating leases 6.5 Finance leases 1.9 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.5 % Lessor Information related to the Company s system leasing During fiscal year ended December 31, 2020, second third 2020. During the fourth December 31, 2020, 12 December 31, 2020, For the sales-type leases, the net investment of the Company’s lease receivable is measured at the commencement date and is included in the Condensed consolidated balance sheets as a component of other current assets and prepaid expenses. As of December 31, 2020, three March 31, 2021 2020. three March 31, 2021, March 31, 2021, Equipment lease revenue for operating lease agreements is recognized over the life of the lease. The amount of operating lease income included in Product revenue in the accompanying Condensed consolidated statements of operations for the three March 31, 2021

Note 12 - Contingencies

Note 12 - Contingencies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 12. The Company is named from time to time as a party to other legal proceedings, product liability, commercial disputes, employee disputes, and contractual lawsuits in the normal course of business. A liability and related charge are recorded to earnings in the Company’s consolidated financial statements for legal contingencies when the loss is considered probable and the amount can be reasonably estimated. The assessment is re-evaluated each accounting period and is based on all available information, including discussion with outside legal counsel. If a reasonable estimate of a known or probable loss cannot be made, but a range of probable losses can be estimated, the low-end of the range of losses is recognized if no not InMode Ltd. filed a complaint with the United States International Trade Commission alleging that Ilooda, Co., Ltd’s Secret RF fractional radiofrequency microneedling system, distributed in the United States by the Company, infringes U.S. Patent No. 10,799,285 "285 not third may As of March 31, 2021 2020, $0, not

Note 13 - Debt

Note 13 - Debt	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 13. Convertible notes, net of unamortized debt issuance costs In March 2021, March 15, 2026 March 15 September 15 September 15, 2021. Initially, each $1,000 may March 15, 2026, No March 31, 2021, Holders may December 15, 2025, $1,000 ● During any fiscal quarter commencing after the fiscal quarter ending on June 30, 2021 ( not ● During the five-business day period after any five consecutive trading day period (the “measurement period”) in which the “trading price” per $1,000 ● The Company calls such Convertible notes for redemption, at any time prior to the close of business on the second ● Upon the occurrence of specified corporate events. On or after December 15, 2025, second may $1,000 As of March 31, 2021, not The Company may not March 20, 2024. March 20, 2024, may 130% 20 not 30 not If a fundamental change occurs, note holders have the option to require the Company to repurchase any portion or all of their Convertible notes in $1,000 100% The Convertible notes are general senior unsecured obligations that rank senior to any of the Company’s indebtedness that is explicitly subordinated to the Notes. The Notes have equal rank in right of payment with all existing and future unsecured indebtedness that is not not The estimated fair value of the Convertible notes was approximately $156.9 million as of March 31, 2021, 2, 3. The following table presents outstanding principal amount and carrying value of the Convertible notes (in thousands): March 31, 2021 December 31, 2020 Outstanding principal amount $ 138,250 $ - Unamortized debt issuance costs (4,665 ) - Carrying Value $ 133,585 $ - In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally designated to reduce the potential dilution of the Company's common stock upon any conversion or settlement of the Notes or to offset any cash payment the Company is required to make in excess of the principal amount upon conversion of the Notes, as the case may not March 4,2021, 40 March 12, 2026. no The Company early adopted ASU 2020 06, 470 20 815 40 470 20 815 40, 2020 06, no Issuance Cost The issuance costs related to the Convertible notes is presented in the Condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. During the three March 31, 2021, The issuance costs are amortized using an effective interest method basis over the term of the Convertible notes and accordingly the Company recorded approximately $52,000 of amortization of debt issuance costs during the three March 31, 2021. The effective interest rate on the Convertible notes is 2.97%. Interest expense for the three March 31, 2021 $243,000, March 31, 2021. Loan and Security Agreement On May 30, 2018, On July 9, 2020, four July 9, 2024. In order to draw on the full amount of the SVB Revolving Line of Credit, the Company must satisfy certain liquidity ratios. If the Company is unable to meet these liquidity ratios, then availability under the revolving line is calculated as 80% of the Company’s qualifying accounts receivable. The proceeds of the revolving loans may five July 9, 2020, twelve The Loan and Security Agreement with Silicon Valley Bank contains customary affirmative covenants, such as financial statement reporting requirements and delivery of borrowing base certificates, as well as customary covenants that restrict the Company’s ability to, among other things, incur additional indebtedness, sell certain assets, guarantee obligations of third twelve March 31, 2021. On March 4, 2021, July 9, 2020 As of March 31, 2021, not The Paycheck Protection Program (PPP) Loan On April 22, 2020, April 21, 2020, April 21, 2022 1.00% September 2021. no may No not The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. Subsequently released guidance instructs all applicants and recipients to take into account their current business activity and the Company's ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not April 28, 2020, $2.0 may first 2021. March 31, 2021. no The PPP loan will be derecognized upon repayment of the loan in accordance with its terms and/or upon confirmation of forgiveness from the SBA.

Note 14 - Segment Reporting

Note 14 - Segment Reporting	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 14. Segment reporting is based on the “management approach,” following the method that management organizes the Company’s reportable segments for which separate financial information is made available to, and evaluated regularly by, the chief operating decision maker in allocating resources and in assessing performance. The Company’s chief operating decision makers ("CODM") are its Chief Executive Officer ("CEO") and Chief Financial Officer (“CFO”), who make decisions on allocating resources and in assessing performance. The CEO and CFO review the Company's consolidated results as one one one The following table presents a summary of revenue by geography for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Revenue mix by geography: United States $ 18,844 $ 13,784 Japan 16,555 7,162 Asia, excluding Japan 2,403 3,229 Europe 4,424 2,816 Rest of World other than United States, Asia and Europe 7,442 5,248 Total consolidated revenue $ 49,668 $ 32,239 Revenue mix by product category: Products $ 28,320 $ 20,958 Consumables 2,925 2,533 Skincare 12,306 2,900 Total product revenue 43,551 26,391 Service 6,117 5,848 Total consolidated revenue $ 49,668 $ 32,239

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Description of Operations and Principles of Consolidation Cutera, Inc. (“Cutera” or the “Company”) provides energy-based aesthetic systems for practitioners worldwide. The Company develops, manufactures, distributes, and markets energy-based product platforms for use by physicians and other qualified practitioners, enabling them to offer safe and effective aesthetic treatments to their customers. The Company currently markets the following system platforms: enlighten, excel, Secret PRO, Juliet, Secret RF, truSculpt xeo Titan, truSculpt 3D,truSculpt truSculpt flex Secret PRO, Juliet Secret RF third Titan, truSculpt 3D, truSculpt flex The Company’s corporate headquarters and U.S. operations are located in Brisbane, California, where the Company conducts manufacturing, warehousing, research and development, regulatory, sales and marketing, service, and administrative activities. The Company also maintains regional distribution centers (“RDCs”) in selection locations across the U.S. These RDCs serve as forward warehousing for systems and service parts in various geographies. The Company markets sells and services the Company’s products through direct sales and service employees in North America (including Canada), Australia, Austria, Belgium, France, Germany, Hong Kong, Japan, Spain, Switzerland, and the United Kingdom. Sales and services outside of these direct markets are made through a worldwide distributor network in over 42
Risks and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not In March 2020 , 19 19 2020 December 31, 2020. third 2020, 19 2021, 19 19 19 no three March 31, 2021 . COVID–19 The Company has experienced a significant increase in sales of skincare products under the exclusive distribution agreement with ZO Skin Health, Inc. (“ZO”), which allows the Company to sell ZO’s skincare products in Japan. The reason for the increase in skincare products sales might have been the result of changes in customers’ spending habits to purchase more aesthetic treatments which could be applied at home due to limitations on in-person aesthetic procedures, social distancing and mask wearing requirements due to the COVID- 19 may 19 may
Unaudited Interim Financial Information [Policy Text Block]	Unaudited Interim Financial Information In the opinion of the Company, the accompanying unaudited Condensed consolidated financial statements included in this report reflect all adjustments (consisting of only normal recurring adjustments) necessary for a fair statement of its Condensed consolidated statements of financial position as of March 31, 2021 2020, three March 31, 2021, 2020. December 31, 2020 not not 10 December 31, 2020 March 23, 2021.
Basis of Accounting, Policy [Policy Text Block]	Accounting Policies These unaudited Condensed consolidated financial statements are prepared in accordance with the rules and regulations of the SEC applicable to interim financial statements. While these statements reflect all normal recurring adjustments that are, in the opinion of management, necessary for fair presentation of the results of the interim period, they do not 10 December 31, 2020 March 23, 2021. The Company uses the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the notes to Condensed consolidated financial statements refer to the Company’s continuing operations. Note 13 The Company issued $138.3 million of convertible senior notes ("Notes" or "Convertible notes") in a private placement offering on March 5, 2021. 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 no The costs associated with issuance of the Convertible notes, including underwriters’ fees are presented in the Condensed consolidated balance sheet as a direct deduction from the carrying amount of the Convertible notes. The debt issuance costs are amortized over the life of the Convertible notes as additional non-cash interest expense. In connection with issuance of the Convertible notes, the Company entered into capped call transactions with certain option counterparties. The capped call transactions are generally designated to reduce the potential dilution of the Company's common stock upon any conversion of the Notes. The capped calls were purchased for $16.1 million and recorded as a reduction to additional paid in capital in the Condensed consolidated balance sheet as of March 31, 2021.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of Condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ materially from those estimates. On an ongoing basis, management evaluates its estimates, including those related to warranty obligations, sales commission, allowance for credit losses, sales allowances, valuation of inventories, fair value of goodwill, useful lives of property and equipment, impairment testing for long-lived-assets, implicit and incremental borrowing rates related to the Company’s leases, assumptions regarding variables used in calculating the fair value of the Company's equity awards, expected achievement of performance based vesting criteria, management performance bonuses, assumptions used in operating and sales-type lease classification, the standalone selling price of the Company's products and services, the period of benefit used to capitalize and amortize contract acquisition costs, variable consideration, contingent liabilities, recoverability of deferred tax assets, residual value of leased equipment, lease term and effective income tax rates. Management bases estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In December 2019, No. 2019 12 Income Taxes (Topic 740 three March 31, 2021. not In August 2020, No. 2020 06, 470 815 no not not may January 1, 2021. 13

Note 2 - Cash, Cash Equivalen_2

Note 2 - Cash, Cash Equivalents (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	(Dollars in thousands) March 31, 2021 December 31, 2020 Cash and cash equivalents $ 164,932 $ 47,047

Note 4 - Balance Sheet Details

Note 4 - Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2021 December 31, 2020 Raw materials $ 15,335 $ 14,874 Work in process 1,359 1,030 Finished goods 17,884 12,604 Total $ 34,578 $ 28,508
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2021 December 31, 2020 Accrued payroll and related expenses $ 12,558 $ 12,197 Sales and marketing accruals 3,134 2,352 Accrued inventory in transit 7,501 2,476 Product warranty 3,351 2,908 Accrued sales tax 6,935 5,343 Other accrued liabilities 7,850 5,803 Total $ 41,329 $ 31,079

Note 5 - Warranty and Extende_2

Note 5 - Warranty and Extended Service Contract (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Three Months Ended March 31, 2021 2020 (1) Beginning Balance $ 2,908 $ 4,401 Add: Accruals for warranties issued during the period 1,525 860 Less: Settlements made during the period (1,082 ) (1,863 ) Ending Balance $ 3,351 $ 3,398

Note 6 - Deferred Revenue (Tabl

Note 6 - Deferred Revenue (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended March 31, 2021 2020 Balance at beginning of quarter $ 11,237 $ 14,222 Add: Payments received 4,929 3,571 Less: Revenue (445 ) (592 ) Less: Revenue included in the beginning balance and recognized as revenue in the current quarter (3,984 ) (4,232 ) Balance at end of quarter $ 11,737 $ 12,969

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity and Stock-based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Options Outstanding Shares Available for Grant Number of Stock Options Outstanding Weighted- Average Price Balance, December 31, 2020 1,085,170 217,007 $ 22.35 Stock awards granted (234,227 ) 68,673 32.87 Options exercised - (24,090 ) 16.41 Options canceled 2,500 (2,500 ) 39.30 Stock awards canceled 58,232 - - Balance, March 31, 2021 911,675 259,090 $ 25.53
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2021 2020 Cost of revenue $ 144 $ 290 Sales and marketing 721 719 Research and development 301 321 General and administrative 680 650 Total stock-based compensation expense $ 1,846 $ 1,980

Note 9 - Net Loss Per Share (Ta

Note 9 - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2021 Three Months Ended March 31, 2020 Numerator: Net loss $ (359 ) $ (12,414 ) Denominator: Weighted average shares of common stock outstanding used in computing net loss per share, basic 17,768 14,433 Dilutive effect of incremental shares and share equivalents - - Weighted average shares of common stock outstanding used in computing net loss per share, diluted 17,768 14,433 Net loss per share: Net loss per share, basic and diluted $ (0.02 ) $ (0.86 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2021 2020 Convertible notes(1)(2) 4,167 - Options to purchase common stock 245 276 Restricted stock units 585 669 Performance stock units 92 216 Employee stock purchase plan shares 30 71 Total 5,119 1,232

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Leases, Financial Statement Information [Table Text Block]	Leases Classification March 31, 2021 December 31, 2020 Assets Right-of-use assets Operating lease assets $ 16,570 $ 17,076 Finance lease Property and equipment, net (1) 418 467 Total leased assets $ 16,988 $ 17,543 Liabilities March 31, 2021 December 31, 2020 Operating lease liabilities Operating lease liabilities, current Operating lease liabilities $ 2,351 $ 2,260 Operating lease liabilities, non-current Operating lease liabilities, net of current portion 15,394 15,950 Total Operating lease liabilities $ 17,745 $ 18,210 Finance lease liabilities Finance lease liabilities, current Accrued liabilities (1) $ 418 $ 370 Finance lease liabilities, non-current Other long-term liabilities 434 241 Total Finance lease liabilities $ 852 $ 611 Three Months Ended March 31, Lease costs 2021 2020 Finance lease cost Amortization expense $ 127 $ 149 Finance lease cost Interest for finance lease $ 14 $ 19 Operating lease cost Operating lease expense $ 878 $ 728 Three Months Ended March 31, Cash paid for amounts included in the measurement of lease liabilities 2021 2020 Operating cash flow Finance lease $ 14 $ 19 Financing cash flow Finance lease $ 115 $ 120 Operating cash flow Operating lease $ 772 $ 727
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	As of March 31, 2021 Amount Remainder of 2021 $ 2,327 2022 3,152 2023 3,189 2024 2,879 2025 2,875 2026 and thereafter 6,308 Total lease payments 20,730 Less: imputed interest 2,985 Present value of lease liabilities $ 17,745
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	As of March 31, 2021 Amount Remainder of 2021 $ 342 2022 377 2023 141 Total lease payments 860 Less: imputed interest 8 Present value of lease liabilities $ 852
Lease, Cost [Table Text Block]	Lease Term and Discount Rate March 31, 2021 Weighted-average remaining lease term (years) Operating leases 6.5 Finance leases 1.9 Weighted-average discount rate Operating leases 4.7 % Finance leases 6.5 %

Note 13 - Debt (Tables)

Note 13 - Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Convertible Debt [Table Text Block]	March 31, 2021 December 31, 2020 Outstanding principal amount $ 138,250 $ - Unamortized debt issuance costs (4,665 ) - Carrying Value $ 133,585 $ -

Note 14 - Segment Reporting (Ta

Note 14 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three Months Ended March 31, 2021 2020 Revenue mix by geography: United States $ 18,844 $ 13,784 Japan 16,555 7,162 Asia, excluding Japan 2,403 3,229 Europe 4,424 2,816 Rest of World other than United States, Asia and Europe 7,442 5,248 Total consolidated revenue $ 49,668 $ 32,239 Revenue mix by product category: Products $ 28,320 $ 20,958 Consumables 2,925 2,533 Skincare 12,306 2,900 Total product revenue 43,551 26,391 Service 6,117 5,848 Total consolidated revenue $ 49,668 $ 32,239

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 05, 2021	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020
Inventory Write-down			$ 200
Proceeds from Convertible Debt			$ 138,250	$ 0
Capped Call Transactions Costs	$ 16,100
Convertible Senior Notes Due 2026 [Member]
Proceeds from Convertible Debt	$ 138,300	$ 138,300
Convertible Senior Notes Due 2026 [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.25%	2.25%	2.25%

Note 2 - Cash, Cash Equivalen_3

Note 2 - Cash, Cash Equivalents (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Marketable Securities, Current, Total	$ 0	$ 0

Note 2 - Cash, Cash Equivalen_4

Note 2 - Cash, Cash Equivalents - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Cash and cash equivalents	$ 164,932	$ 47,047

Note 4 - Balance Sheet Detail_2

Note 4 - Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020		Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	[1]
Standard Product Warranty Accrual, Ending Balance	$ 3,351	$ 3,398	[1]		$ 2,908	$ 4,401
Extended Product Warranty Accrual, Ending Balance	1,000	1,800
Standard Product Warranty Accrual, Decrease for Payments	1,082	1,863	[1]
Extended Product Warranty Accrual, Decrease for Payments	200			$ 3,200
Product Remediation Liability [Member]
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued, Total				$ 5,000
Standard Product Warranty Accrual, Ending Balance	400				400
Extended Product Warranty Accrual, Ending Balance	1,000				$ 1,200
Standard Product Warranty Accrual, Decrease for Payments	0	0
Extended Product Warranty Accrual, Decrease for Payments	$ 200	$ 200
[1]	The ending product warranty accrual balance excludes $1.0 million and $1.8 million as of March 31, 2021 and 2020 and one-time extended service contracts cost to replace components in one of the Company's legacy products.

Note 4 - Balance Sheet Detail_3

Note 4 - Balance Sheet Details - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Raw materials	$ 15,335	$ 14,874
Work in process	1,359	1,030
Finished goods	17,884	12,604
Total	$ 34,578	$ 28,508

Note 4 - Balance Sheet Detail_4

Note 4 - Balance Sheet Details - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued payroll and related expenses	$ 12,558	$ 12,197
Sales and marketing accruals	3,134	2,352
Accrued inventory in transit	7,501	2,476
Product warranty	3,351	2,908
Accrued sales tax	6,935	5,343
Other accrued liabilities	7,850	5,803
Total	$ 41,329	$ 31,079

Note 5 - Warranty and Extende_3

Note 5 - Warranty and Extended Service Contract (Details Textual) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020		Dec. 31, 2018
Extended Product Warranty Accrual, Decrease for Payments	$ 200			$ 3,200
Extended Product Warranty Accrual, Ending Balance	1,000	$ 1,800
Standard Product Warranty Accrual, Decrease for Payments	$ 1,082	$ 1,863	[1]
[1]	The ending product warranty accrual balance excludes $1.0 million and $1.8 million as of March 31, 2021 and 2020 and one-time extended service contracts cost to replace components in one of the Company's legacy products.

Note 5 - Warranty and Extende_4

Note 5 - Warranty and Extended Service Contract - Summary of Warranties (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	[1]
Beginning Balance	$ 2,908	$ 4,401
Add: Accruals for warranties issued during the period	1,525	860
Less: Settlements made during the period	(1,082)	(1,863)
Ending Balance	$ 3,351	$ 3,398
[1]	The ending product warranty accrual balance excludes $1.0 million and $1.8 million as of March 31, 2021 and 2020 and one-time extended service contracts cost to replace components in one of the Company's legacy products.

Note 6 - Deferred Revenue (Deta

Note 6 - Deferred Revenue (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue, Remaining Performance Obligation, Percentage	85.00%
Revenue, Remaining Performance Obligation, Amount	$ 11.7
Costs for Extended Service Contracts	$ 2	$ 2.2

Note 6 - Deferred Revenue - Sum

Note 6 - Deferred Revenue - Summary of Deferred Service Contract Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Balance at beginning of quarter	$ 11,237	$ 14,222
Add: Payments received	4,929	3,571
Less: Revenue	(445)	(592)
Less: Revenue included in the beginning balance and recognized as revenue in the current quarter	(3,984)	(4,232)
Balance at end of quarter	$ 11,737	$ 12,969

Note 7 - Revenue (Details Textu

Note 7 - Revenue (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Contract with Customer, Liability, Total	$ 11,737	$ 12,969	$ 11,237	$ 14,222
Selling and Marketing Expense [Member]
Capitalized Contract Cost, Amortization	500	$ 700
Other Assets [Member]
Capitalized Contract Cost, Net, Total	3,400		3,400
Loyalty [Member]
Contract with Customer, Liability, Total	$ 400		$ 300
Transferred over Time [Member] | Service [Member]
Revenue, Performance Obligation Transferred over Time, Percent	12.00%	18.00%

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($) $ in Millions	Apr. 28, 2021	Aug. 02, 2020	Jun. 14, 2019	Jun. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2019
Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		60,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					88,588
Performance Shares [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							67,897
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)							4 years
Performance Shares [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		22,423
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		2 years 6 months
Performance Shares [Member] | Chief Financial Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	8,971
Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other Than Options, Vested in Period, Percentage	40.00%
Performance Shares [Member] | Tranche 2019 [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							10,185
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)						8,657
Performance Shares [Member] | Tranche 2020 [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						0	16,974
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							25.00%
Performance Shares [Member] | Tranche 2020 [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	16,974
Performance Shares [Member] | Tranche 2021 [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							20,369
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							30.00%
Performance Shares [Member] | Tranche 2022 [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							20,369
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							30.00%
Performance Shares [Member] | Vesting Based on Finance Department Goals [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		40.00%
Performance Shares [Member] | Vesting Based on Company Performance Goals [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		60.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)					56,597
Non-qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					68,673
Restricted Stock Units (RSUs) and Non-qualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					4 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Monthly Percentage after First Year					2.78%
Restricted Stock Units (RSUs) and Non-qualified Stock Options [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					25.00%
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 1.6
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					3 years 10 months 24 days
Share-based Payment Arrangement, Option [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		5 years
Restricted Stock Units and Performance Share Units [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total					$ 13.9
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 1 month 6 days
Two Thousand Nineteen Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)			700,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			9,701,192
Stock Issued During Period, Shares, New Issues (in shares)					122,694
The Amended and Restated 2019 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)				600,000

Note 8 - Stockholders' Equity_4

Note 8 - Stockholders' Equity and Stock-based Compensation Expense - Activity Under the 2004 Equity Incentive Plan (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Balance, shares available for grant (in shares)	1,085,170
Balance, stock options outstanding (in shares)	217,007
Balance, weighted-average exercise price (in dollars per share) | $ / shares	$ 22.35
Stock awards granted, shares available for grant (in shares)	(234,227)
Options exercised, stock options outstanding (in shares)	(24,090)
Options exercised, weighted-average exercise price (in dollars per share) | $ / shares	$ 16.41
Options canceled, shares available for grant (in shares)	2,500
Options canceled, stock options outstanding (in shares)	(2,500)
Options canceled, weighted-average exercise price (in dollars per share) | $ / shares	$ 39.30
Stock awards canceled (in shares)	58,232
Balance, shares available for grant (in shares)	911,675
Balance, stock options outstanding (in shares)	259,090
Balance, weighted-average exercise price (in dollars per share) | $ / shares	$ 25.53

Note 8 - Stockholders' Equity_5

Note 8 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense By Department (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Allocated Share Based Compensation Expense	$ 1,846	$ 1,980
Cost of Sales [Member]
Allocated Share Based Compensation Expense	144	290
Selling and Marketing Expense [Member]
Allocated Share Based Compensation Expense	721	719
Research and Development Expense [Member]
Allocated Share Based Compensation Expense	301	321
General and Administrative Expense [Member]
Allocated Share Based Compensation Expense	$ 680	$ 650

Note 9 - Net Loss Per Share (De

Note 9 - Net Loss Per Share (Details Textual)	1 Months Ended	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2021
Convertible Senior Notes Due 2026 [Member]
Debt Instrument, Convertible, Number of Equity Instruments	4,167,232	4,167,232

Note 9 - Net Loss Per Share - N

Note 9 - Net Loss Per Share - Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss	$ (359)	$ (12,414)
Weighted average shares of common stock outstanding used in computing net loss per share, basic (in shares)	17,768	14,433
Dilutive effect of incremental shares and share equivalents (in shares)	0	0
Weighted average shares of common stock outstanding used in computing net loss per share, diluted (in shares)	17,768	14,433
Net loss per share, basic and diluted (in dollars per share)	$ (0.02)	$ (0.86)

Note 9 - Net Loss Per Share - A

Note 9 - Net Loss Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities (in shares)		5,119	1,232
Convertible Debt Securities [Member]
Antidilutive Securities (in shares)	[1],[2]	4,167	0
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)		245	276
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)		585	669
Performance Shares [Member]
Antidilutive Securities (in shares)		92	216
ESPP [Member]
Antidilutive Securities (in shares)		30	71
[1]	Anti-dilutive convertible notes were calculated under the if-converted method for the three months ended March 31, 2021.
[2]	The Company entered into capped call transactions with certain financial institutions, which are generally designated to reduce common stock dilution upon conversion of the Convertible notes. The capped call transactions are excluded from the computation of diluted net loss per common share as their effect would be anti-dilutive.

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Expense (Benefit), Total	$ 258,000	$ 78,000

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Sales-type Lease, Revenue	$ 0	$ 0
Proceeds From Exercise of Purchase Option Sales Type Lease	100
Operating Lease, Lease Income, Total	100
Other Current Assets [Member]
Sales-type and Direct Financing Leases, Lease Receivable	$ 600		$ 700
Minimum [Member]
Lessee, Leases, Remaining Term (Year)	1 year
Maximum [Member]
Lessee, Leases, Remaining Term (Year)	10 years
Lessee, Lease, Renewal Term (Year)	5 years

Note 11 - Leases - Financial St

Note 11 - Leases - Financial Statement Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Right-of-use assets		$ 16,570		$ 17,076
Total leased assets		16,988		17,543
Operating lease liabilities, current		2,351		2,260
Operating lease liabilities, non-current		15,394		15,950
Present value of lease liabilities		17,745		18,210
Finance lease liabilities, current	[1]	418		370
Finance lease liabilities, non-current		434		241
Present value of lease liabilities		852		611
Finance lease cost		127	$ 149
Finance lease cost		14	19
Operating lease cost		878	728
Operating cash flow		14	19
Financing cash flow		115	120
Operating cash flow		772	$ 727
Operating Lease Assets [Member]
Right-of-use assets		16,570		17,076
Operating Lease Liabilities [Member]
Operating lease liabilities, current		2,351		2,260
Property and Equipment, Net [Member]
Finance lease	[2]	418		467
Operating Lease Liabilities, Net of Current Portion [Member]
Operating lease liabilities, non-current		$ 15,394		$ 15,950
[1]	Finance lease liabilities included in Accrued liabilities in the condensed consolidated balance sheets.
[2]	Finance lease assets included in Property and equipment, net in the condensed consolidated balance sheets.

Note 11 - Leases - Maturities o

Note 11 - Leases - Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Remainder of 2021	$ 2,327
Present value of lease liabilities	17,745	$ 18,210
Facility Operating Leases [Member]
2022	3,152
2023	3,189
2024	2,879
2025	2,875
2026 and thereafter	6,308
Total lease payments	20,730
Less: imputed interest	2,985
Present value of lease liabilities	$ 17,745

Note 11 - Leases - Maturities_2

Note 11 - Leases - Maturities of Finance Leases Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Present value of lease liabilities	$ 852	$ 611
Vehicle Finance Leases [Member]
Remainder of 2021	342
2022	377
2023	141
Total lease payments	860
Less: imputed interest	8
Present value of lease liabilities	$ 852

Note 11 - Leases - Lease Inform

Note 11 - Leases - Lease Information (Details)	Mar. 31, 2021
Operating leases (Year)	6 years 6 months
Finance leases (Year)	1 year 10 months 24 days
Operating leases	4.70%
Finance leases	6.50%

Note 12 - Contingencies (Detail

Note 12 - Contingencies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Estimated Litigation Liability	$ 400	$ 0

Note 13 - Debt (Details Textual

Note 13 - Debt (Details Textual)	Mar. 05, 2021USD ($)	Jul. 09, 2020USD ($)	Apr. 22, 2020USD ($)	Mar. 31, 2021USD ($)$ / shares$ / item	Mar. 31, 2021USD ($)$ / shares$ / item	Mar. 31, 2020USD ($)	Mar. 04, 2021$ / shares	Dec. 31, 2020USD ($)	May 30, 2018USD ($)
Proceeds from Convertible Debt					$ 138,250,000	$ 0
Convertible Debt, Noncurrent				$ 133,585,000	$ 133,585,000			$ 0
Derivative, Cap Price (in USD per Per Share) | $ / item				45.5350	45.5350
Derivative Cap Price Premium Over Stock Price, Percent				75.00%	75.00%
Share Price (in dollars per share) | $ / shares							$ 26.02
Payments for Derivative Instrument, Financing Activities				$ 16,100,000	$ 16,134,000	$ 0
Debt Issuance Costs, Gross				4,700,000	4,700,000
Amortization of Debt Issuance Costs					52,000
Interest Expense, Total					243,000
Revolving Line of Credit [Member] | Wells Fargo [Member]
Line of Credit Facility, Maximum Borrowing Capacity									$ 25,000,000
Revolving Credit Facility [Member]
Long-term Line of Credit, Total				0	0
Accrued Liabilities [Member]
Interest Payable				191,000	$ 191,000
Convertible Senior Notes Due 2026 [Member]
Proceeds from Convertible Debt	$ 138,300,000			138,300,000
Proceeds from Debt, Net of Issuance Costs				$ 133,600,000
Debt Instrument, Convertible, Conversion Ratio				30.1427
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 33.18	$ 33.18
Debt Instrument, Convertible, Number of Equity Instruments				4,167,232	4,167,232
Convertible Debt, Noncurrent				$ 133,600,000	$ 133,600,000
Debt Instrument, Unamortized Discount, Total				4,700,000	4,700,000
Debt Instrument, Convertible, If-converted Value in Excess of Principal				138,300,000
Debt Instrument, Convertible, Required Outstanding Amount Not Subject to Redemption				50,000,000	$ 50,000,000
Debt Instrument, Interest Rate During Period					2.97%
Convertible Senior Notes Due 2026 [Member] | Fair Value, Inputs, Level 2 [Member]
Convertible Debt, Fair Value Disclosures				$ 156,900,000	$ 156,900,000
Convertible Senior Notes Due 2026 [Member] | Redeemable on or After March 2020-24 [Member]
Debt Instrument, Redemption Price, Percentage				100.00%
Convertible Senior Notes Due 2026 [Member] | Convertible Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.25%			2.25%	2.25%
Convertible Senior Notes Due 2026, First Conversion Trigger [Member]
Debt Instrument, Convertible, Threshold Trading Days				20
Debt Instrument, Convertible, Threshold Consecutive Trading Days				30
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				130.00%
Convertible Senior Notes Due 2026, Second Conversion Trigger [Member]
Debt Instrument, Convertible, Threshold Trading Days				5
Debt Instrument, Convertible, Threshold Consecutive Trading Days				5
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger				98.00%
Loan and Security Agreement [Member] | Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Line of Credit Facility, Maximum Borrowing Capacity		$ 30,000,000
Debt Instrument, Term (Year)		4 years
Debt Instrument, Percentage of Qualifying Accounts Receivable		80.00%
Line of Credit Facility, Commitment Fee Amount		$ 300,000
Debt Instrument, Anniversary Fee Amount		$ 300,000
Debt Covenant, Quarterly Minimum Revenue					$ 90,000,000
Loan and Security Agreement [Member] | Revolving Credit Facility [Member] | Silicon Valley Bank [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Long-term Debt, Total			$ 7,100,000

Note 13 - Debt - Outstanding De

Note 13 - Debt - Outstanding Debt and Carrying Value (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Unamortized debt issuance costs	$ (4,665)
Convertible Senior Notes Due 2026 [Member]
Outstanding principal amount	138,250	$ 0
Unamortized debt issuance costs	(4,665)	0
Carrying Value	$ 133,585	$ 0

Note 14 - Segment Reporting (De

Note 14 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2021
Number of Operating Segments	1

Note 14 - Segment Reporting - S

Note 14 - Segment Reporting - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 49,668	$ 32,239
Products Excluding Consumables and Skincare [Member]
Revenue	28,320	20,958
Consumables [Member]
Revenue	2,925	2,533
Skincare [Member]
Revenue	12,306	2,900
Product [Member]
Revenue	43,551	26,391
Service [Member]
Revenue	6,117	5,848
UNITED STATES
Revenue	18,844	13,784
JAPAN
Revenue	16,555	7,162
Asia, Excluding Japan [Member]
Revenue	2,403	3,229
Europe [Member]
Revenue	4,424	2,816
Rest of World [Member]
Revenue	$ 7,442	$ 5,248